Ray Dalio's VRTX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 27,488 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $12.46 M, representing 0.05% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 187,000 shares. Largest reduction occurred in Q2 2024, reducing 101,466 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -10,836 | Reduce 28.27% | 27,488 | $453.36 |
| Q3 2025 | +3,934 | Add 11.44% | 38,324 | $391.64 |
| Q2 2025 | +34,390 | New Buy | 34,390 | $445.20 |
| Q1 2025 | -710 | Sold Out | 0 | $0.00 |
| Q4 2024 | -2,742 | Reduce 79.43% | 710 | $402.70 |
| Q3 2024 | -29,777 | Reduce 89.61% | 3,452 | $465.08 |
| Q2 2024 | -101,466 | Reduce 75.33% | 33,229 | $468.72 |
| Q1 2024 | +2,341 | Add 1.77% | 134,695 | $418.01 |
| Q4 2023 | -25,995 | Reduce 16.42% | 132,354 | $406.89 |
| Q3 2023 | -17,964 | Reduce 10.19% | 158,349 | $347.74 |
| Q2 2023 | -27,963 | Reduce 13.69% | 176,313 | $351.91 |
| Q1 2023 | +103,457 | Add 102.62% | 204,276 | $315.07 |
| Q4 2022 | -63,172 | Reduce 38.52% | 100,819 | $288.78 |
| Q3 2022 | -53,161 | Reduce 24.48% | 163,991 | $289.54 |
| Q2 2022 | +187,000 | Add 620.19% | 217,152 | $281.79 |
| Q1 2022 | +17,735 | Add 142.83% | 30,152 | $260.98 |
| Q4 2021 | -2,700 | Reduce 17.86% | 12,417 | $219.62 |
| Q3 2021 | -8,139 | Reduce 35.00% | 15,117 | $181.39 |
| Q2 2021 | +1,567 | Add 7.22% | 23,256 | $201.63 |
| Q1 2021 | +18,059 | Add 497.49% | 21,689 | $214.90 |
| Q4 2020 | +3,630 | New Buy | 3,630 | $236.36 |
| Q4 2019 | -32,260 | Sold Out | 0 | $0.00 |
| Q3 2019 | +32,260 | New Buy | 32,260 | $169.40 |
| Q2 2019 | -21,889 | Sold Out | 0 | $0.00 |
| Q1 2019 | +21,889 | New Buy | 21,889 | $183.93 |
| Q3 2018 | -15,509 | Sold Out | 0 | $0.00 |
| Q2 2018 | +15,509 | New Buy | 15,509 | $169.97 |
| Q3 2017 | -18,673 | Sold Out | 0 | $0.00 |
| Q2 2017 | +18,673 | New Buy | 18,673 | $128.85 |
Ray Dalio's Vertex Pharmaceuticals Incorporated Investment FAQs
Ray Dalio first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q2 2017, acquiring 18,673 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Vertex Pharmaceuticals Incorporated (VRTX) for 29 quarters since Q2 2017.
Ray Dalio's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q2 2022, adding 217,152 shares worth $61.19 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 27,488 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $12.46 M.
As of the Q4 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.05% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 217,152 shares, as reported at the end of Q2 2022.